Mao Yin

731 total citations
31 papers, 421 citations indexed

About

Mao Yin is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Molecular Biology. According to data from OpenAlex, Mao Yin has authored 31 papers receiving a total of 421 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Oncology, 15 papers in Radiology, Nuclear Medicine and Imaging and 8 papers in Molecular Biology. Recurrent topics in Mao Yin's work include HER2/EGFR in Cancer Research (16 papers), Monoclonal and Polyclonal Antibodies Research (13 papers) and Radiopharmaceutical Chemistry and Applications (8 papers). Mao Yin is often cited by papers focused on HER2/EGFR in Cancer Research (16 papers), Monoclonal and Polyclonal Antibodies Research (13 papers) and Radiopharmaceutical Chemistry and Applications (8 papers). Mao Yin collaborates with scholars based in United States, China and South Korea. Mao Yin's co-authors include Gregory L. Baker, A. Tulinsky, K. Padmanabhan, Dmitry R. Gumerov, Timothy B. Lowinger, Natalya D. Bodyak, Robert A. Goyer, Elena Ter‐Ovanesyan, LiuLiang Qin and Mikhail Papisov and has published in prestigious journals such as Journal of Biological Chemistry, Biochemistry and Cancer Research.

In The Last Decade

Mao Yin

28 papers receiving 389 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mao Yin United States 11 154 120 120 110 72 31 421
Hari Krishna R. Santhapuram United States 15 234 1.5× 333 2.8× 111 0.9× 129 1.2× 222 3.1× 21 694
Prakash Sai India 6 86 0.6× 242 2.0× 121 1.0× 42 0.4× 53 0.7× 8 386
Péter Lázár Hungary 7 146 0.9× 185 1.5× 122 1.0× 70 0.6× 27 0.4× 9 426
María Loreto Bravo Chile 10 118 0.8× 117 1.0× 109 0.9× 11 0.1× 13 0.2× 21 375
Tetsuo Morinaga Japan 7 90 0.6× 148 1.2× 148 1.2× 47 0.4× 48 0.7× 8 541
Sandra Roche Ireland 12 193 1.3× 207 1.7× 65 0.5× 26 0.2× 56 0.8× 27 440
Chiara Barozzi Italy 13 130 0.8× 224 1.9× 22 0.2× 18 0.2× 27 0.4× 25 534
Suzanne J. Bakewell United States 10 282 1.8× 184 1.5× 34 0.3× 38 0.3× 94 1.3× 19 520
Janine P. Wereley United States 10 135 0.9× 133 1.1× 34 0.3× 34 0.3× 74 1.0× 16 365
H. H. Schrenk Germany 9 93 0.6× 147 1.2× 112 0.9× 103 0.9× 15 0.2× 24 440

Countries citing papers authored by Mao Yin

Since Specialization
Citations

This map shows the geographic impact of Mao Yin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mao Yin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mao Yin more than expected).

Fields of papers citing papers by Mao Yin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mao Yin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mao Yin. The network helps show where Mao Yin may publish in the future.

Co-authorship network of co-authors of Mao Yin

This figure shows the co-authorship network connecting the top 25 collaborators of Mao Yin. A scholar is included among the top collaborators of Mao Yin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mao Yin. Mao Yin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Pan, Hai‐Tao, Qing Zhang, Ganyuan Xiao, et al.. (2025). Abstract 2945: PLB-002 is a novel Claudin 6 antibody-drug conjugate for ovarian cancer and testicular germ cell cancer. Cancer Research. 85(8_Supplement_1). 2945–2945. 1 indexed citations
3.
Thomas, Joshua D., Mao Yin, Natalya D. Bodyak, et al.. (2024). Development of a Novel DNA Mono-alkylator Platform for Antibody–Drug Conjugates. Molecular Cancer Therapeutics. 23(4). 541–551.
4.
Thomas, Joshua D., Mao Yin, Natalya D. Bodyak, et al.. (2022). Discovery of novel polyamide-pyrrolobenzodiazepine hybrids for antibody-drug conjugates. Bioorganic & Medicinal Chemistry Letters. 72. 128876–128876. 3 indexed citations
5.
Conlon, Patrick R., Michael D. Kaufman, Yuanyuan Li, et al.. (2022). Process Development and GMP Production of a Conjugate Warhead: Auristatin F-HPA-Ala/TFA (XMT-1864/TFA). Organic Process Research & Development. 26(8). 2124–2137. 1 indexed citations
6.
Clardy, Susan M., Mao Yin, Dmitry R. Gumerov, et al.. (2018). Abstract 754: Unique pharmacologic properties of Dolaflexin-based ADCs—a controlled bystander effect. Cancer Research. 78(13_Supplement). 754–754. 8 indexed citations
7.
Bergstrom, Donald A., Natalya D. Bodyak, Laura L. Poling, et al.. (2017). MA09.10 A NaPi2b Antibody-Drug Conjugate Induces Durable Complete Tumor Regressions in Patient-Derived Xenograft Models of NSCLC. Journal of Thoracic Oncology. 12(1). S396–S397. 3 indexed citations
8.
Gumerov, Dmitry R., Dongmei Xiao, Joshua D. Thomas, et al.. (2016). Abstract 596: Optimization of lead antibody selection for XMT-1522, a novel, highly potent HER2-targeted antibody-drug conjugate (ADC). Cancer Research. 76(14_Supplement). 596–596. 2 indexed citations
9.
10.
Yin, Mao, Natalya D. Bodyak, Joshua D. Thomas, et al.. (2015). A Polymer-Based Antibody–Vinca Drug Conjugate Platform: Characterization and Preclinical Efficacy. Cancer Research. 75(16). 3365–3372. 73 indexed citations
11.
Bergstrom, Donald A., Natalya D. Bodyak, Peter U. Park, et al.. (2015). Abstract LB-231: A novel, highly potent HER2-targeted antibody-drug conjugate (ADC) for the treatment of low HER2-expressing tumors and combination with trastuzumab-based regimens in HER2-driven tumors. Cancer Research. 75(15_Supplement). LB–231. 12 indexed citations
12.
Smith, Roger A., Nitin K. Damle, Sanjeeva Reddy, et al.. (2015). Abstract 1693: ASN004, a novel 5T4-targeted Dolaflexin™ antibody drug conjugate, causes complete regression in multiple solid tumor models. Cancer Research. 75(15_Supplement). 1693–1693. 2 indexed citations
13.
Yin, Mao, et al.. (2009). Abstract #1572: Pharmacokinetics of a novel fumagillol conjugate XMT-1107 in the rat. Cancer Research. 69. 1572–1572. 1 indexed citations
14.
Papisov, Mikhail, Alan J. Fischman, Alex Hiller, et al.. (2007). MER-1001, a novel polymeric prodrug of camptothecin, is a potent inhibitor of LS174 and A2780 human tumor xenografts in a mouse model. Cancer Research. 67. 781–781. 6 indexed citations
15.
Yin, Mao, et al.. (2004). Synthesis of a Macromolecular Camptothecin Conjugate with Dual Phase Drug Release. Molecular Pharmaceutics. 1(5). 375–382. 28 indexed citations
16.
Seshadri, T. P., Ewa Skrzypczak‐Jankun, Mao Yin, & A. Tulinsky. (1994). Differences in the Metal Ion Structure between Sr- and Ca-Prothrombin Fragment 1. Biochemistry. 33(5). 1087–1092. 12 indexed citations
17.
Goyer, Robert A. & Mao Yin. (1967). Taurine and Creatine Excretion after X-Irradiation and Plasmocid-Induced Muscle Necrosis in the Rat. Radiation Research. 30(2). 301–301. 7 indexed citations
18.
Sun, Gang, et al.. (1967). The Renal Tubule in Experimental Lead Intoxication. Journal of Occupational and Environmental Medicine. 9(10). 536–536. 8 indexed citations
19.
Goyer, Robert A., Mao Yin, & D. H. Bowden. (1964). Taurine Excretion Following Drug-Induced Muscle Necrosis and X-Irradiation.. Experimental Biology and Medicine. 116(2). 534–536. 9 indexed citations
20.
Mahowald, Theodore A., Mao Yin, John T. Matschiner, et al.. (1958). BILE ACIDS. Journal of Biological Chemistry. 230(2). 581–588. 36 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hari Krishna R. Santhapuram Breakdown of academic impact, for papers by Prakash Sai Breakdown of academic impact, for papers by Péter Lázár Breakdown of academic impact, for papers by María Loreto Bravo Breakdown of academic impact, for papers by Tetsuo Morinaga Breakdown of academic impact, for papers by Sandra Roche Breakdown of academic impact, for papers by Chiara Barozzi Breakdown of academic impact, for papers by Suzanne J. Bakewell Breakdown of academic impact, for papers by Janine P. Wereley Breakdown of academic impact, for papers by H. H. Schrenk
Rankless by CCL
2026